Cancer Hormone Therapy Market By Therapy Type | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cancer Hormone Therapy Market
Cancer Hormone Therapy Market: By Therapy Type (Neoadjuvant & Adjuvant Treatment), By Cancer Treated (Breast, Prostate, Ovarian, Thyroid, Kidney & Other Cancers) & By Geography-Forecast (2016-2021)
Report Code : HCR 0196
Updated Date: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Hormones are natural substances produced by glands in our bodies. They are carried in our bloodstream and act as messengers between one part of our body and another. Hormone therapy for cancer is the use of medicines to block the effects of hormones which are used by some of the cancers to grow. Cancer hormone therapy does not work for all types of cancer. However doctors and surgeons use hormone therapy for people with cancers that are hormone sensitive or hormone dependent.

This report identifies the cancer hormone therapy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cancer hormone therapy market.
 
Cancer Hormone Therapy Market

Globally North America dominated the market for cancer hormone therapy in 2015 due to higher usage of the latest and advanced technologies for treatment and high awareness and reported instances of cancer in the region. North America is expected to continue its domination during the period of study and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement in the field of medical science, increasing medical tourism coupled with increasing awareness about cancer in the region.

This report on cancer hormone therapy also covers different type of cancer hormone therapy available, various cancer treated and market size in various geographical regions.

  • On the basis of type of cancer hormone therapy this report classifies as follows covering all major types of cancer hormone therapy available in the market: Neoadjuvant treatment and Adjuvant treatment
  • On the basis of cancer treated with cancer hormone therapy this report covers all the major cancer treated using cancer hormone therapy: Breast Cancer, Prostate Cancer, Ovarian Cancer, Thyroid Cancer and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cancer hormone therapy in each of the region.

Sample Companies Profiled in this Report are: 
  • Novartis International AG
  • AstraZeneca Plc
  • Merck and Co.     
  • Pfizer Inc     
  • QuatRx Pharmaceuticals
  • 10+
1. Cancer Hormone Therapy – Market Overview
2. Executive Summary 
3. Cancer Hormone Therapy Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Cancer Hormone Therapy – Market Forces
   4.1. Drivers
      4.1.1. Increasing global instances of cancer and cancer related deaths
      4.1.2. Increasing practice towards alternative cancer therapy
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cancer Hormone Therapy Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Cancer Hormone Therapy Market, By Therapy Type 
   6.1. Neoadjuvant treatment
   6.2. Adjuvant treatment
7. Cancer Hormone Therapy Market, By Cancer Treated
   7.1. Breast Cancer
   7.2. Prostate Cancer
   7.3. Ovarian Cancer
   7.4. Thyroid Cancer
   7.5. Kidney Cancer
   7.6. Others
8. Cancer Hormone Therapy Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America 
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Cancer Hormone Therapy – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Novartis International AG
      10.1.1.  Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. AstraZeneca Plc
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Merck and Co.     
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Pfizer Inc     
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. QuatRx Pharmaceuticals   
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Eli Lilly and Company     
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Seattle Genetics  
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Bayer Healthcare      
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Sanofi   
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Boehringer-Ingelheim       
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll